MenaQ7

What MenaQ7 does

MenaQ7 is a B2B ingredient brand that manufactures and supplies clinically validated Vitamin K2 as menaquinone-7 (MK-7) to dietary supplement manufacturers, functional food and beverage producers, and brand formulators worldwide. The core technology is a patented natural fermentation process using non-GMO Bacillus strains on an allergen-free substrate, producing MK-7 with general purity exceeding 97% and 99.8% isomeric purity in the bioactive all-trans form. The portfolio includes MenaQ7 (the flagship MK-7 ingredient) and MenaQ7 Matrix (an award-winning protective technology variant for clean-label formulations), plus extensions such as MenaQ7 Full Spectrum and MenaQ7 Metabolic.

MenaQ7 is operated by Gnosis by Lesaffre, a business unit of the French Lesaffre Group (a global fermentation conglomerate), with administrative headquarters in Marcq-en-Baroeul, France, and a registered office in Paris. The company has been developed through nearly two decades of clinical research, with more than 22 human clinical trials published in peer-reviewed journals including JAMA Cardiology, and holds patents on arterial health benefits in the US, Israel, and Australia. Its competitive position rests on clinical evidence depth, a broad regulatory and certification stack (cGMP, ISO 22000, Non-GMO, GRAS, EFSA Novel Food, Halal, Kosher, Vegan, Gluten-Free), and global distribution in 30+ countries via regional distributors and direct sales.

The business model is B2B ingredient sales, generating revenue through direct sales and ingredient licensing/royalty arrangements with brand partners who incorporate MenaQ7 into finished products. Pricing is quote-based and not publicly disclosed, typically under multi-year contracts. Go-to-market is built on scientific and educational marketing — white papers, industry publications, trade shows (Vitafoods, SupplySide), and YouTube/LinkedIn content — targeting R&D and product development professionals. Primary customers include premium supplement brands (Dr. Mercola, Lyma, Wiley's Finest, WelleCo, TrueOsteo, Australian NaturalCare), functional food partners (Tirlán for dairy fortification), and a long tail of SMB formulators across multiple health verticals including bone, cardiovascular, pediatric, women's health, and sports nutrition.

Name

MenaQ7

Legal name

Gnosis by Lesaffre

Website

https://menaq7.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

MenaQ7 is a B2B ingredient brand operated by Gnosis by Lesaffre that manufactures clinically validated Vitamin K2 as MK-7 via patented natural fermentation, supplying dietary supplement and functional food manufacturers worldwide across 30+ countries.

Ownership category

akta.pro rank

Product category

Nutritional Ingredients (Vitamin K2 / MK-7)

NAICS

Spice and Extract Manufacturing (311942)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Vitamins (A, B-Complex, C, D, E, K; Premixes) (AFAJAKAA)

akta.pro secondary industry

Fortification Ingredients (Vitamins, Minerals, Nutrient Premixes) (CRADAOAM)

Keywords

• Vitamin K2 ingredients
• Menaquinone-7 MK-7
• Nutritional raw materials
• Bone health supplements
• Cardiovascular health ingredients

Headquarters

HQ city

Marcq-en-baroeul

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Marketing or Sales, Personnel

Revenue model

1. B2B Ingredient Sales: MenaQ7 generates revenue by selling Vitamin K2 as MK-7 as a branded ingredient to dietary supplement manufacturers, functional food companies, and other product formulators worldwide. Revenue is generated through ingredient licensing and direct sales to brand partners who incorporate MenaQ7 into their finished products.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

MenaQ7 manufactures and supplies clinically validated, patented Vitamin K2 as MK-7 (menaquinone-7) as a B2B branded ingredient for dietary supplement and functional food manufacturers. The ingredient is produced via natural fermentation using non-GMO Bacillus strains, achieving 97%+ general purity and 99.8% all-trans isomeric purity, and is offered in core and Matrix-protected variants backed by more than 22 human clinical trials.

Product overview

MenaQ7 is a B2B ingredient company offering clinically validated Vitamin K2 as MK-7 (menaquinone-7) supplements. The portfolio consists of two main products: MenaQ7® (the core clinically validated Vitamin K2 ingredient derived from natural fermentation) and MenaQ7® Matrix (a protected formulation variant using proprietary matrix technology for enhanced stability in complex supplement formulations). Both products target bone health and cardiovascular health applications and are sold as ingredients to finished product manufacturers.

Differentiator

Problem solved

Functional benefit

Brands

• MenaQ7 Matrix: Award-winning Vitamin K2 Matrix protective technology that protects MK-7 particles without coating, additives, or additional ingredients, offering clean-label formulation options
• MenaQ7 Full Spectrum
• MenaQ7 Metabolic

Products and services

• MenaQ7® Vitamin K2 as MK-7 Clinically validated Vitamin K2 as MK-7 (menaquinone-7) ingredient derived from natural fermentation using non-GMO Bacillus strains, achieving 97%+ general purity and 99.8% all-trans isomeric purity. Sold B2B to dietary supplement and functional food manufacturers for bone and cardiovascular health applications.
• MenaQ7® Matrix Protected variant of MenaQ7 MK-7 using proprietary Vitamin K2 Matrix technology that protects particles from moisture and mineral salts during shelf life without coating or additives. Designed as a clean-label alternative for complex dietary supplement formulations requiring enhanced stability.

Quantifiable outcome

• 29% lower progression in coronary artery calcification Agatston score vs placebo over 24 months
• +5 more outcomes

Named customers10 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core.

• TirláncoreStrategic or Co-development Partner · 7 August 2024Gnosis by Lesaffre and Tirlán partnered on a joint initiative to reveal emerging healthy aging trends and promote bone strength nutrition. The collaboration combined Gnosis by Lesaffre's MenaQ7 Vitamin K2 expertise with Tirlán's dairy and nutrition capabilities to educate consumers about bone health and the importance of Vitamin K2 supplementation.
• Maastricht UniversitycoreStrategic or Co-development Partner · 31 May 2018NattoPharma partnered with Maastricht University and ISHF (International Society for Heart Research) to develop a Recommended Daily Intake (RDI) for Vitamin K2. The research partnership aimed to establish scientific basis for Vitamin K2 intake recommendations.
• Norwegian Research CouncilcoreStrategic or Co-development Partner · 1 February 2017NattoPharma Research Network was awarded EU funding grant and €4 million research grant from the Norwegian Research Council to drive additional research into Vitamin K2's health benefits and applications.
• NattoPharma US Patent on Arterial BenefitscoreTechnology or Integration · 1 June 2016NattoPharma received US patent protection for the arterial health benefits of MenaQ7 Vitamin K2, establishing intellectual property protection for cardiovascular applications of the ingredient.
• Gnosis by LesaffrecoreStrategic or Co-development PartnerMenaQ7 is operated by Gnosis by Lesaffre, a business unit of Lesaffre. Gnosis by Lesaffre acquired NattoPharma (the original developer of MenaQ7) to expand its human health ingredient portfolio with Vitamin K2 as MK-7.

Scale indicators4 records

Recent moves1 record

Expansion highlights6 records

Broad incumbents

• BASF Nutrition & Health: BASF is one of the world's largest producers of vitamins (including K vitamins) and nutritional ingredients for human and animal nutrition, making it a key broad incumbent competing with MenaQ7 in the global vitamin ingredient supply market.
• Glanbia Nutritionals: Glanbia Nutritionals supplies proteins, premixes, vitamins, and functional ingredients to supplement and functional food brands globally, comparable to MenaQ7 as a B2B ingredient supplier targeting bone, joint, and sports-nutrition categories.
• ADM Nutrition: ADM is a global nutrition giant offering a broad ingredient portfolio (vitamins, flavors, proteins, functional ingredients) to food, beverage, and supplement manufacturers, comparable to MenaQ7 as a B2B ingredient supplier with much broader scope.
• DSM-Firmenich: DSM-Firmenich is a global nutrition and health ingredient powerhouse producing a broad vitamin portfolio (including K vitamins) for human nutrition, animal nutrition, and personal care, serving as a broader incumbent that overlaps MenaQ7 in the B2B vitamin ingredient market.
• Balchem Corporation: Balchem is a specialty ingredient manufacturer serving human nutrition and health markets with encapsulated vitamins, minerals, and nutrient systems for supplement manufacturers, comparable to MenaQ7 as a B2B ingredient supplier with a nutritional focus.
• Lallemand: Lallemand is a global fermentation-specialist peer to Lesaffre/Gnosis producing nutritional yeasts, probiotics, and fermentation-derived ingredients for human and animal health, adjacent in technology and customer base to MenaQ7's Bacillus-based fermentation platform.
• Lonza Capsules & Health Ingredients: Lonza is a major contract manufacturer and supplier of nutritional and pharmaceutical ingredients, including vitamins and fermentation-derived health ingredients, positioning it as a broad incumbent in the same B2B health-ingredient category as MenaQ7.
• Kerry Group: Kerry Group supplies functional ingredients and taste solutions to food, beverage, and supplement manufacturers globally, including vitamins and fortification premixes, making it a broader incumbent overlapping MenaQ7 in the functional-food ingredient category.

Direct peers

• Kappa Bioscience: Kappa Bioscience produces K2Vital, a leading Vitamin K2 as MK-7 ingredient competing directly with MenaQ7 in the same B2B nutraceutical supply space, with similar clinical positioning targeting bone and cardiovascular health.

Others

• Novonesis (formerly Novozymes): Novonesis is a biotechnology and enzyme/fermentation platform supplier underpinning many B2B bio-manufactured nutrition ingredients; comparable to MenaQ7's parent Lesaffre as a fermentation technology ecosystem participant enabling bio-ingredient production.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCeKAB_byxxPZ17nCzuP6pUQ
• LinkedInlinkedin.com/company/1861785
• Xx.com/thenattopharma

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MenaQ7